We have assessed the ability of bispecific fusion proteins to improve adenovirus-mediated transfer of therapeutic and marker transgenes. We constructed an expression vector that can be easily modified to synthesize a variety of fusion proteins for retargeting adenoviral gene therapy vectors to cell surface markers, which are differentially expressed between normal and cancer cells. Adenoviral transduction can be improved in a number of tumour cell lines which overexpress EGFR (epidermal growth factor receptor) or uPAR (urokinase-type plasminogen activator receptor), but which have only low levels of endogenous hCAR (human coxsackie B and adenovirus receptor) expression. Up to 40-fold improvement in b-galactosidase transgene expression was seen using an EGFR retargeting protein, and up to 16-fold using a second fusion protein targeting uPAR. In vitro, our uPAR retargeting fusion protein improved the sensitivity to adenoviral herpes simplex virus thymidine kinase/ganciclovir by an order of magnitude, whereas in vivo, our EGFR retargeting protein is able to significantly delay tumour growth in rodent animal models in a dose-dependent manner. The 'cassette' design of our fusion protein constructs offers a flexible method for the straightforward synthesis of multiple adenoviral retargeting proteins, directed against a variety of tumour-associated antigens, for use in clinical trials.
Introduction
Adenovirus-mediated cancer gene therapy is yet to fulfil its clinical potential. A variety of factors may account for this, including vector losses when delivered systemically, immune clearance, incomplete spread through the tumour bulk, limited cell entry due to lack of appropriate cell surface receptors, inefficient transgene expression, limited cytotoxicity of existing therapeutic genes and inappropriate expression in non-tumour tissues. 1 Much attention has focussed on improving the entry of viral vectors into tumour cells, including 'retargeting' of adenoviral gene therapy vectors by modifying viral tropism, 2 such that the vector preferentially binds to and enters tumour cells rather than normal cells. In this way, there is potential for improving therapeutic index and enhancing clinical efficacy.
Although adenoviral vectors are able to interact directly with a v -integrins, 3 major histocompatibility complex-1, 4 heparan sulphate glycosaminoglycans 5 and coagulation factor X, 6 it is widely accepted that the primary human adenovirus receptor is the coxsackie B and adenovirus receptor (hCAR). 1, 7 Transient transfection of hCAR into a panel of hCAR-deficient ovarian cancer cell lines increased adenoviral transduction. 8, 9 Similar findings were reported in bladder cancer cell lines, in which stable transfection of hCAR into hCARnegative cells and antisense hCAR into hCAR-positive cells modified adenoviral gene transfer. 10 hCAR is expressed on the surface of a wide variety of normal cells, but its expression is reduced in bladder cancer specimens in a stage-and grade-dependent manner. 11 hCAR expression is also reduced/lost in many cancer cell types including bladder 11, 12 and ovarian 9 cancers. Although gene therapy aimed at reversing this relative hCAR underexpression by introducing exogenous hCAR might improve transduction efficiency, a more elegant strategy is to modify adenoviral tropism towards a nonhCAR cell surface target. 2, 13 These targeting strategies aimed at achieving selective hCAR-independent transduction of tumour cells can be sub-divided into 'genetic' and 'conjugate-based' targeting strategies. The genetic targeting approach involves modification of the viral genome, for example, the introduction of integrinbinding RGD motifs, [14] [15] [16] or the construction of chimeric adenoviruses, in which a heterologous fibre knob gene is incorporated into a serotype 5 genome. 18 The conjugate-based approach involves the production of antibody conjugates, 19 or bispecific fusion proteins. 20 Polymer-coating of viruses has also been used successfully to retarget adenoviruses selectively to different cell types such as ovarian cancer. 21 These 'adaptor molecule' methods do not involve genetic modification of the viral genome, thereby permitting rapid production of bulk quantities in vitro and, in principle, allowing retargeting of any adenovirus vector by any characterized cell surface protein.
The epidermal growth factor receptor (EGFR; h-erbB1) is a potential target for tumour-selective retargeted delivery of adenoviral gene therapy vectors for a variety of tumour types. EGFR is overexpressed in many tumour types such as breast, bladder, colorectal, lung, prostate and ovarian cancers. [22] [23] [24] In transgenic mice, this relative overexpression has been shown to promote bladder tumour growth and urothelial hyperplasia, 25 and in human bladder cancer specimens is associated with poor prognosis. 26, 27 In addition to overexpression, point mutations within the kinase domain of EGFR have proved to be useful in predicting the response to anti-EGFR-targeted therapies, particularly, in non-small cell lung cancer. 28 A predictor of response to EGFR-targeted therapies has also emerged in colorectal cancer, the Kirsten Ras (K-ras) status. Patients with wild-type K-ras status demonstrate a better clinical response to cetuximab compared with mutant K-ras status. 29 Alternative, clinically relevant targets for tumour-selective retargeting of adenoviral vectors include the urokinase-type plasminogen activator (uPAR), a key regulator of cancer cell invasion and metastasis. 30, 31 Overexpression has been described as a prognostic indicator in a variety of cancers including breast, 32 colorectal, and upper gastrointestinal cancers. 33, 34 It is also a prognostic indicator for bladder cancer 35, 36 and is known to be upregulated in human bladder tumour specimens. 37 We have extended the 'conjugate' approach of Dmitriev et al. 20 to investigate whether bispecific fusion proteins can be used to improve adenoviral transduction of a panel of bladder tumour cell lines and/or reduce transduction of normal urothelial cells. We describe the production of two fusion proteins, in which the extracellular domain of hCAR is fused with polypeptide sequences, which bind to the cell surface receptors EGFR and uPAR, respectively. As a prelude to potential clinical trials of adenoviral cancer gene therapy, we have tested their ability to modify adenoviral transduction of a panel of human cancer cell lines in vitro and in vivo.
Results
Design, production and purification of the fusion protein constructs Fusion proteins in which the extracellular domain of hCAR is fused with polypeptide sequences that bind to the cell surface receptors EGFR and uPAR were constructed ( Figure 1a ). Protein elution from HeLa cells transiently transfected with pQE-sCAR-L-EGF 53 and pQEsCAR-L-Pro-uPA resulted in the generation of His-tagged fusion proteins at the predicted molecular weights (35 and 75 kDa, respectively) ( Figure 1b) . Although purified sCAR-L-EGF 53 was found predominantly in the elution fragment, most of the sCAR-L-Pro-uPA fusion protein remained in the supernatant after bead incubation. This inefficient purification may be due to the His-tag being folded within the protein, and therefore inaccessible to the Ni-beads. The 60 kDa band seen in both eluates is considered to be a nonspecific protein, as it was seen in all purifications performed in the HeLa cell system with this expression plasmid construct. Design of our plasmid expression vector includes the ability to express protein in bacterial, insect or mammalian cells. Better yields of protein, required for subsequent in vivo studies, were therefore obtained from insect cells by incorporating our construct into a baculovirus expression vector. Baculovirus expression of the sCAR-L-EGF 53 fusion Bispecific fusion proteins for adenoviral retargeting TJ Harvey et al protein resulted in a product of the same size as that observed in the HeLa/plasmid expression system and was able to produce B10 times more recombinant protein ( Figure 1c) . Furthermore, the nonspecific protein of 60 kDa was not observed in the baculovirus-derived protein preparations.
Retargeting Ad-CMV-lacZ to SKOV3 cells using sCAR-L-EGF 53 The SKOV3 ovarian cancer cell line was chosen as an appropriate model for testing sCAR-L-EGF 53 , as it has very low/undetectable hCAR expression, but overexpresses EGFR to an extent greater than any other cell line we have investigated (Figure 2a (Figures 2d and e) , suggesting that adenoviral entry mediated by sCAR-L-EGF 53 depends predominantly on the expression of EGFR. An 'irrelevant' neutralizing antibody was also used as a control without any reduction in adenoviral retargeting (data not shown). The observation that reversal of retargeting with neutralizing antibody was incomplete is consistent with the possibility that additional nonspecific interactions may be contributing to adenoviral entry, in addition to specific receptor-mediated mechanisms. 
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TJ Harvey et al 5637 cell lines are transduced to a greater extent than was predicted from the hCAR expression data, perhaps suggesting the involvement of alternative hCARindependent methods of entry. Adenoviral transduction of a number of the bladder cancer cell lines is improved with addition of sCAR-L-EGF 53 . For example, the T24 cell line is naturally refractory to adenoviral transduction, but is converted into a relatively passive cell line after retargeting using the fusion protein sCAR-L-EGF 53 .
The enhancement of T24 cell transduction corresponds to an 11-fold improvement in b-galactosidase activity compared with untargeted cells (Figure 3c ). In order to assess any correlation between retargeting and protein expression, quantitation of the FACS plots was performed by comparing the geometric mean fluorescence index for each curve ( Figure 3c ) and calculating an EGFR/hCAR ratio. In six of the eight cell lines tested, a good relationship between the retargeting achieved (dark bars) and the EGFR/hCAR expression ratio (light bars) was found. The four cell lines with the highest EGFR/ hCAR ratios showed the greatest retargeting and the four with the lowest ratios were retargeted least effectively.
Effects of EGFR retargeting in normal urothelial cells
Although the sCAR-L-EGF 53 fusion protein is useful in improving adenoviral gene transfer in cells with low hCAR/high EGFR expression, a second potential benefit of adenoviral retargeting would be to reduce/restrict adenoviral entry into cells with a high hCAR/low EGFR expression profile-the expected profile of a normal cell. In order to test this hypothesis, three normal human urothelial (NHU) cell lines were investigated. Figure 4a demonstrates that the three NHU cell lines express hCAR at varying but relatively high levels, and also have low but detectable levels of EGFR. As seen in our previous work, 38 all three were permissive to viral entry and showed similar levels of transduction in the absence of retargeting protein to those seen in tumour cell lines in the presence of sCAR-L-EGF 53 . However, after addition of 50 ng sCAR-L-EGF 53 , adenoviral entry was not hindered, but rather was slightly increased in each of three NHU cell lines (Figure 4b ). We hypothesized that the low levels of EGFR seen in NHU cells might provide an additional binding opportunity, permitting entry of the virus into NHU cells by either CAR and/or EGFR. In support of this, incubation of NHU cells with antibodies against CAR and/or EGFR, before the addition of the Ad-CMV-lacz/sCAR-L-EGF 53 mix, reduced adenoviral transduction of NHU cells to the levels seen with virus alone (Figure 4c) . A similar pattern was seen with two other NHU cell lines (data not shown).
UPAR as an alternative receptor for adenoviral retargeting
Although many clinical bladder tumour specimens overexpress EGFR, 23 the heterogeneity of tumour tissue makes it unlikely that targeting EGFR alone will be sufficient for all bladder tumours, and additional or alternative cell surface targets are likely to be required for clinically useful therapy. We therefore investigated uPAR as a potential alternative target using a second fusion protein, sCAR-L-Pro-uPA. The majority of bladder cancer cell lines investigated express uPAR as assessed In analogous experiments to those with sCAR-L-EGF 53 above, the ability of sCAR-L-Pro-uPA to retarget adenovirus to NHU cells was investigated (Figure 5d ). As with sCAR-L-EGF 53 , the uPA retargeting protein slightly increased the binding of Ad-CMV-lacZ to the NHU cell line, rather than hindering viral entry. Again, preincubation of the NHU cells with antibodies against uPAR and/ or CAR, separately or together, reduced the levels of b-galactosidase activity to those seen with virus alone, suggesting that virus can enter NHU cells by CAR and/or uPAR. A similar pattern was seen with two other NHU cell lines (data not shown).
Retargeting of a therapeutic adenovirus using sCAR-L-Pro-uPA
In (hCAR-negative, uPAR-positive) J82 cells, addition of 100 ng sCAR-L-Pro-uPA resulted in a 10-fold improvement in IC 50 using Ad-CMV-HSVtk (herpes simplex virus thymidine kinase) and ganciclovir (GCV) (Figure 6 ), suggesting a marked increase in the sensitivity of these tumour cells to GCV in the presence of our fusion protein. This significant improvement in transgenemediated cell-kill emphasizes the potential of this targeting strategy, transforming J82 cells from a GCV-resistant line when treated with adenovirus alone into a cell line that is highly susceptible when retargeting fusion protein is added.
In vivo enhancement of adenoviral gene therapy using sCAR-L-EGF 53
The ability of Ad-CMV-HSVtk/GCV to delay tumour growth in the absence or presence of sCAR-L-EGF 53 protein was examined in a SKOV3 xenograft model in nude mice. To maintain similar ratios of virus to protein to those used in vitro, 1 Â 10 8 plaque-forming units (PFU) of Ad-CMV-HSVtk was pre-mixed with 20 or 50 mg of protein and injected intratumourally. No significant impact on tumour growth was seen for protein alone, saline or untreated control groups. Although virus preincubated with 20 mg of protein administered to mice showed no effect on tumour growth compared with virus alone, with or without GCV (data not shown), statistically significant effects were seen when 50 mg of protein was used. A significant delay in tumour growth (Pp0.05) was seen when tumours were treated with naked virus and GCV, compared with virus alone, but an even greater effect (Pp0.03) was seen when virus was pre-mixed with 50 mg of sCAR-L-EGF 53 protein (Figure 7) . These results reflect those obtained for the in vitro studies, in which 50 ng of protein was sufficient to demonstrate significant retargeting of the adenovirus to high EGFR/low CAR expressing cells with the same ratio of virus to protein, and importantly demonstrate that the strategy is effective in more complex in vivo models.
Discussion
We have examined the effectiveness of bispecific fusion proteins in improving adenoviral transduction of tumour cell lines that are intrinsically refractory to adenoviral transduction. We demonstrate in vitro that the sCAR-L-EGF 53 48 demonstrated a similar 12-fold increase in adenoviral entry to that seen here, by using an EGFR-targeting bispecific single chain antibody in multiple bladder cancer cell lines. A second study, also using bladder cancer cell lines, demonstrated an improvement in adenoviral infection using a retargeting strategy directed to the RGDmediated integrins and Ad3 receptors. 18 A number of other approaches to modifying the natural tropism of adenoviral vectors for hCAR have been reported. For example, Martin et al. 49 also exploited overexpression of uPAR to improve adenoviral infectivity of liver cells by incorporating a uPAR-binding ligand into the H1 loop of the adenoviral fibre knob. However, we believe that our system has a number of advantages. First, the 'cassette' design of our fusion protein expression construct allows both flexibility and rapid, efficient production of a variety of fusion proteins. In principle, any cell surface molecule that is overexpressed in cancer cells, and for which a known ligand has been characterized, can be targeted. Second, the genetic modification approach to altering adenoviral tropism requires time-consuming modification of the adenoviral fibre knob domain and lengthy bulking-up of each virus that is to be retargeted; whereas a single fusion protein can be used to retarget almost any adenoviral vector, whether they are replication-defective or conditionally replicating, and whether they express marker or therapeutic transgenes. Third, the ease with which these fusion proteins can be expressed and purified may allow simultaneous use of multiple retargeting fusion proteins to target a range of heterogeneous tumours without detailed characterization of their cell surface expression pattern.
Previous studies in our laboratory have demonstrated that NHU cells are readily infectable using adenoviruses. 38 Vectors expressing a therapeutic transgene may therefore produce an undesirable cell kill in normal cells. On the basis of our hCAR/EGFR expression data, we predicted that the addition of our fusion proteins to NHU cells (high hCAR, low EGFR and low uPAR) would interfere with adenoviral entry, thus reducing NHU cytotoxicity and providing an extra therapeutic advantage in a mixed population of tumour and normal cells, such as would be seen in a clinical setting. In fact, addition of the fusion proteins caused a modest increase in adenoviral transduction of the NHU cells, rather than a decrease. Our data suggest that, unlike the situation in hCAR-poor tumour cells, adenoviral entry to NHU cells may be possible by both the retargeted receptor and hCAR. Nevertheless, the increase in transduction seen with retargeting protein in NHUs is clearly less than that seen in tumour cells, suggesting that a differential effect could still be achieved.
Although a good correlation between the relative expression of EGFR/hCAR and the potential for adenoviral retargeting has been shown for the majority of cell lines tested, correlation was not perfect. A possible explanation is the presence of an EGFR-and hCAR-independent mechanism of viral entry. Alternatively, a rate-limiting step other than viral attachment may explain the variability observed. Certainly, caution must be exercised in predicting the success of retargeting experiments on the basis of protein expression profiles alone.
Our observation that the use of uPAR retargeting protein can increase the sensitivity of tumour cells to adenovirus-mediated HSVtk/GCV in vitro, and especially to cells not rendered passive by EGFR retargeting, confirms the flexibility of our system and implies that different tumours may require alternative retargeting approaches. Using a similar sCAR-EGF fusion protein to that used here, Liang et al. 50 successfully retargeted an adenovirus containing a marker gene to tumour cell line xenografts expressing EGFR, and showed a good increase in adenoviral targeting, demonstrating that the adenovirus/protein complex is stable in vivo. However, they did not test viruses expressing a therapeutic gene.
Our demonstration that retargeting fusion proteins can enhance transduction of tumour cells by an adenoviral vector expressing the HSVtk transgene, and delay the growth of tumour xenografts in vivo suggests that this strategy would be amenable to use in clinical trials of cancer gene therapy. Future clinical use might be in one of two scenarios. The first would be an individualized therapeutic approach. Patient biopsies would be taken and tumour expression profiles obtained. A decision could then be made as to whether a patient was suitable for use of a particular fusion protein, and if so, which one was appropriate for treatment. This 'individualized therapy' would be subject to the above limitation of the imperfect correlation between expression patterns and transduction efficiency. The second approach would be to use a 'cocktail' of multiple fusion proteins to target a single adenovirus to multiple cell surface markers commonly overexpressed in tumours. The plasmid-based 'cassette' design of our basic vector allows the synthesis of such a cocktail, more easily and more rapidly than multiple genetic modifications of the adenoviral genome. This approach is attractive as, using tumour array analysis from a large number of patients, a panel of 'optimum targets' could be established. A mixture of retargeting proteins would then direct adenoviral vector entry towards one or more of these, thereby efficiently targeting a large proportion of patients' tumours without any prior knowledge of the characteristics of an individual tumour.
In conclusion, this approach represents an opportunity to improve adenoviral gene therapy strategies, in multiple cancer types, and can be utilized in combination with existing and future adenovirus-mediated gene therapy strategies to further enhance tumour/tissue-selective Bispecific fusion proteins for adenoviral retargeting TJ Harvey et al expression of therapeutic genes. Our in vivo data suggest that this strategy is amenable to testing in clinical trials of hCAR-poor tumours.
Materials and methods

Cell culture
Established human tumour cell lines (transitional cell carcinoma cell lines, RT112, 5637, JON, VMCUB1, RT4, T24, UMUC3, J82; ovarian cancer cell line, SKOV3; cervical carcinoma cell line, HeLa) were grown in monolayer culture at 37 1C in a humidified atmosphere containing 5% CO 2 . NHU cells were cultured from surgical specimens of ureter and renal pelvis as described previously, 51 and maintained in keratinocyte serum-free medium supplemented with bovine pituitary extract and recombinant EGF, which were added according to the manufacturers' instructions to give final concentrations of 50 and 5 ng ml À1 , respectively. Cholera toxin was included at 30 ng ml
À1
.
Fusion protein construct production pQE-sCAR-LINKER Intermediate. RNA was isolated from RT4 cells using RNeasy (Qiagen, West Sussex, UK), according to the manufacturer's protocols. First-strand cDNA was produced using Omniscript (Qiagen) from 1 mg of isolated RNA using oligo-dT as a primer. The fulllength coding sequence of hCAR was PCR amplified from the RT4 cDNA using sequence-specific primers, 5
0 -a ggagcgagagccgcctac-3 0 and 5 0 -acggagagcacagatgagaca-3 0 . The PCR product was gel extracted, TA-cloned into pGEM-Teasy (Promega, Southampton, UK), and nested PCR primers were used to amplify the extracellular domain of hCAR (sCAR), 5 0 -ccatggcgctcctgctgtgc-3 0 and 5 0 -ctgcagagctttatttgaaggagggacaacg-3 0 . The nested primers contained additional 5 0 -NcoI (forward) and 5 0 -PstI (reverse) restriction-site recognition sequences for subsequent cloning steps. The resulting sCAR PCR product was TA-cloned into pGEM-Teasy, excised using an NcoI/ PstI digest and inserted into the expression plasmid pQE-TriSystems (Qiagen), which contains an 8 Â His-tag epitope to facilitate protein purification steps. The resulting intermediate construct was designated pQEsCAR. To produce the linker peptide composed of the amino-acid sequence (SASASASAP), two oligonucleotides 5 0 -gtccgcaagtgcctcagcgtctgctccaggtac-3 0 and 5 0 -c tggagcagacgctgaggcacttgcggactgca-3 0 containing PstI and KpnI restriction-site overhangs were annealed and inserted into pQE-sCAR. The resulting plasmid was named pQE-sCAR-LINKER.
pQE-sCAR-L-EGF 53 . The full-length EGF coding sequence was PCR amplified from lambda EGF116 phage lysate (ATCC(R); 93-12; 59956) using sequence-specific primers, 5 0 -gtcaatcatactcaccttgcc-3 0 and 5 0 -caggcattgagt aggtgattagtcg-3 0 . The PCR product was gel extracted, TAcloned into pGEM-Teasy, and nested primers were used to PCR amplify a 53 amino-acid peptide encoding the mature form of human EGF (EGF 53 ), 5
0 -ggtaccaatagtg actctgaatgtcc-3 0 and 5 0 -ctcgaggcgcagttcccaccacttcag-3 0 . The nested primers contained additional 5 0 -KpnI (forward) and 5 0 -XhoI (reverse) restriction-site recognition sequences necessary for further cloning steps. The PCR product was TA-cloned, producing pGEM-EGF 53 , and excised using KpnI and XhoI. EGF 53 was then inserted into pQE-sCAR-LINKER, producing pQEsCAR-L-EGF 53 .
pQE-sCAR-L-Pro-uPA. RNA was isolated from T24 cells and reverse transcribed to produce cDNA, as above. The cDNA was used as a template to PCR amplify the entire Pro-uPA coding sequence using sequence-specific primers, 5 0 -ctcctgccgcaggccaccgag-3 0 and 5 0 -gctgatgga gatgactctactgc-3 0 . The PCR product was gel extracted and TA-cloned. The complete coding sequence was PCR amplified using sequence-specific primers including 5 0 -KpnI (forward) and 5 0 -XhoI (reverse) restrictionsite overhangs, 5 0 -ggtaccatgagagccctgctggcgcg-3 0 and 5 0 -ctcgaggagggccaggccattctcttc-3 0 . The PCR product was TA-cloned, gel extracted and excised using KpnI and XhoI. The KpnI/XhoI fragment was ligated into pQEsCAR-LINKER, producing pQE-sCAR-L-Pro-uPA.
Protein purification and detection
Two micrograms of expression plasmid DNA was transiently transfected into 1 Â 10 6 HeLa cells in each of four 10-cm dishes using Effectene (Qiagen) according to the manufacturer's instructions. After 48 h, cells were lifted using phosphate-buffered saline (PBS)/0.1% EDTA, and resuspended in 1 ml of lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 0.05% Tween-20, 10 mM imidazole, pH 8.0). Cell lysate was then sonicated (six 15 s bursts at room temperature with 10 s gaps on ice), and centrifuged (13 000 r.p.m., 10 min, 4 1C). Supernatant was collected and 65 ml of magnetic nickel beads (Qiagen) were added. The supernatant/bead mixture was incubated on an end-over roller at 4 1C for 1 h, before beads were collected and protein was eluted. Beads were washed three times in wash buffer 1 (as above, but 25 mM imidazole), once in wash buffer 2 (as above but 100 mM imidazole), and eluted using 60 ml elution buffer (as above but 250 mM imidazole). A volume of 10 and 2 ml of purified protein was then analysed on a Coomassie-stained gel, and an anti-His western blot, respectively, to assess purity and quantity.
For large-scale production of the sCAR-L-EGF 53 fusion protein, the same pQE construct was recombined with BacPAK6 baculoviral DNA by co-transfection into Spodoptera frugiperda (Sf9) insect cells according to the manufacturer's protocol (Clontech, Saint-Germainen-Laye, France). Plaques were screened for protein expression and specificity by western blot analysis and a recombinant virus stock was prepared. For preparation of recombinant protein, four to six 150 cm 2 flasks were seeded with 2 Â 10 7 Sf9 cells and infected at an multiplicity of infection of 5-10 for 3 days at 27 1C. The cells were then harvested using a cell scraper and pelleted at 1300 r.p.m. for 10 mins at 4 1C. The pellet was resuspended in 3 ml of buffer 1 (10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 1.5 mM MgCl 2 , 10 mM 2-ME) with protease inhibitors and incubated on ice for 30 mins. The cells were then pelleted at 13 000 r.p.m. for 10 mins at 4 1C and the pellet resuspended in 3 ml of buffer 2 (20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10 mM MgCl 2 , 0.5% Triton X-100, 20% glycerol, 10 mM 2-ME) with protease inhibitors and sonicated with four bursts of 30 s each on ice. The lysate was centrifuged again at 13 000 r.p.m. for 10 mins at 4 1C and the supernatant rotated overnight at 4 1C with 200 ml of magnetic nickel Bispecific fusion proteins for adenoviral retargeting TJ Harvey et al beads (Qiagen). The beads were washed with 3 ml of buffer A (20 mM Tris-HCl, pH 8, 500 mM KCl, 10% glycerol, 10 mM 2-ME, 20 mM imidazole) with protease inhibitors and then the protein was eluted in 200 ml of buffer B (20 mM Tris-HCl, pH 8, 100 mM KCl, 10% glycerol, 10 mM 2-ME, 250 mM imidazole). The protein concentration was measured using the Nanodrop spectrophotometer (Thermo Fisher Scientific, Loughborough, UK) and the purity was examined by Coomassie-stained SDS-polyacrylamide gel electrophoresis.
Western blotting
Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred on to a nitrocellulose membrane overnight at 40 V in transfer buffer (20 
Replication-defective adenovirus production
Ad-CMV-lacZ was purchased from Invitrogen (Paisley, UK), and bulked-up, purified and titred as previously described 38 . Ad-CMV-HSVtk was produced using pAdEasy (Stratagene, Agilent Technologies, La Jolla, CA, USA). The full-length CMV (cytomegalovirus) promoter was PCR-amplified from Ad-CMV-lacZ genomic DNA using the sequence-specific primers, 5 0 -tcaatattggccattagcca-3 0 and 5 0 -gctagcctatagtgagtcgtatta-3 0 . The PCR product was TA-cloned into pGEMTeasy, excised using a NotI digest and ligated into pGL3-basic to produce pGL3-CMV. pBS-SK/MEEP-tk was a generous gift from Georges Vassaux (CRUK, Imperial College, London). HSVtk was excised using HindIII/XbaI, and inserted into pGL3-CMV downstream of the cloned CMV promoter. CMV-HSVtk was then excised using a NotI/XbaI partial digest, and inserted into pSHUTTLE. Progression to a primary viral lysate was performed according to the manufacturer's protocols (Stratagene). Adenoviral bulk-up, CsCl purification, and quantitation was performed by ViraQuest (North Liberty, IA, USA). All multiplicities of infection shown are stated in terms of PFU per cell.
In vitro retargeting of marker transgene vectors
Cells were plated out at 1 Â 10 5 cells per well in a 24-well plate, and left overnight. A volume of 1 Â 10 5 PFU ml À1 of Ad-CMV-lacZ was added to varying amounts of retargeting fusion protein (pQE-sCAR-L-EGF 53 or pQE-sCAR-LPro-uPA, 1-100 ng) to produce a final volume of 35 ml. The adenovirus/fusion protein mixture was pipette-mixed and incubated at room temperature for 1 h. Cells were washed in medium containing 2% fetal calf serum, and 165 ml of medium was added to each well. The 35 ml adenovirus/protein mix was then added to the cells and gently mixed to produce a final volume of 200 ml. The mixture was incubated at room temperature for 1 h with occasional gentle agitation. Cells were washed once with medium, and then 1 ml complete medium was added. After overnight incubation, cells were either stained for bgalactosidase activity as previously described 38 or assayed for b-galactosidase activity using GalactoStar (Applied Biosystems, Foster City, CA, USA), according to the manufacturers' instructions. Briefly, cells were lysed in 200 ml lysis buffer, and 10 ml of cleared lysate was added to 100 ml of 50:1 buffer dilution solution/reagent in a 96-well plate. The plate was incubated for 30 min at room temperature with continual agitation, and luminescence measured in a 1450 Micro-b Liquid Scintillation and Luminescence Counter (Wallac, Perkin Elmer, Cambridge, UK). For tumour cell line experiments involving EGFR neutralizing antibodies, cells were preincubated with varying concentrations of anti-EGFR antibody Ab-1 (EMD Biosciences, San Diego, CA, USA) for 1 h at 37 1C/5% CO 2 in medium containing 2% fetal calf serum, prior to addition of virus +/À retargeting fusion protein. For NHU-blocking experiments, the anti-EGFR antibodies Ab-1 or cetuximab (Merck Serono, Geneva, Switzerland) or anti-uPAR antibody FL-290: (sc-10815, Santa Cruz Biotechnology) and/or anti-CAR antibody (Upstate Biotechnology, Lake Placid, NY, USA) were added at 10 mg ml À1 to the cells for 1 h, prior to addition of virus +/À retargeting fusion protein.
In vitro cytotoxicity assays
Cells were plated at 1 Â 10 5 cells per well in a 24-well plate, and left overnight. 1 Â 10 5 PFU ml À1 of Ad-CMVHSVtk was added to 50 ng retargeting fusion protein to produce a final volume of 35 ml. Adenoviral retargeting was performed as described above. After overnight incubation, cells were trypsinized, replated at 5000 cells per well in a 96-well plate, and left overnight. The appropriate concentration of GCV was added to the cells in complete medium, at varying concentrations. Cells were incubated for 5 days before cell viability was assessed using WST-1 (Roche Diagnostics, Burgess Hill, UK). Briefly, 100 ml of a 1:10 dilution of WST-1/medium was added per well of the 96-well plate, and incubated at 37 1C for 45 min. Absorbance was then measured at 420 and 650 nm on a Fluostar Galaxy 96-well plate reader (MTX Lab Systems, Vienna, VA, USA).
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